Promising Outcomes Reported For a Personalized Vaccine Against Cutaneous Melanoma

A new study is utilizing personalized immunotherapy to target specific tumor-associated genomic changes in an effort to combat tumors formed during cutaneous melanoma. The dendritic cell vaccine is tailored to recognize each patient’s tumor, which is thought to be the driving force underlying its ability to proficiently stimulate the immune system.